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Mammalian nuclear TRUB1, mitochondrial TRUB2,
and cytoplasmic PUS10 produce conserved pseudouridine
55 in different sets of tRNA
SHAONI MUKHOPADHYAY,1 MANISHA DEOGHARIA,2 and RAMESH GUPTA
Department of Biochemistry and Molecular Biology, Southern Illinois University, Carbondale, Illinois 62901-4413, USA

ABSTRACT
Most mammalian cytoplasmic tRNAs contain ribothymidine (T) and pseudouridine (Ψ) at positions 54 and 55, respectively.
However, some tRNAs contain Ψ at both positions. Several Ψ54-containing tRNAs function as primers in retroviral DNA
synthesis. The Ψ54 of these tRNAs is produced by PUS10, which can also synthesize Ψ55. Two other enzymes, TRUB1
and TRUB2, can also produce Ψ55. By nearest-neighbor analyses of tRNAs treated with recombinant proteins and subcellular extracts of wild-type and specific Ψ55 synthase knockdown cells, we determined that while TRUB1, PUS10, and
TRUB2 all have tRNA Ψ55 synthase activities, they have different tRNA structural requirements. Moreover, these activities
are primarily present in the nucleus, cytoplasm, and mitochondria, respectively, suggesting a compartmentalization of Ψ55
synthase activity. TRUB1 produces the Ψ55 of most elongator tRNAs, but cytoplasmic PUS10 produces both Ψs of the
tRNAs with Ψ54Ψ55. The nuclear isoform of PUS10 is catalytically inactive and specifically binds the unmodified
U54U55 versions of Ψ54Ψ55-containing tRNAs, as well as the A54U55-containing tRNAiMet. This binding inhibits
TRUB1-mediated U55 to Ψ55 conversion in the nucleus. Consequently, the U54U55 of Ψ54Ψ55-containing tRNAs are modified by the cytoplasmic PUS10. Nuclear PUS10 does not bind the U55 versions of T54Ψ55- and A54Ψ55-containing elongator tRNAs. Therefore, TRUB1 is able to produce Ψ55 in these tRNAs. In summary, the tRNA Ψ55 synthase activities of
TRUB1 and PUS10 are not redundant but rather are compartmentalized and act on different sets of tRNAs. The significance
of this compartmentalization needs further study.
Keywords: tRNA modification; pseudouridine synthase; PUS10 isoforms; subcellular localization; Pus4; retroviral primer

INTRODUCTION
The “TΨC” or “common” arm of a typical tRNA is a 17base stem–loop structure at position 49–65, with a consensus “GUUCRANUC” sequence at position 53–61, the
“UUCRANU” of which forms a loop capping a five base
pair stem (Gupta 1985; Juhling et al. 2009). The eukaryotic
initiator tRNAs and some elongator tRNAs differ from this
consensus. TΨC refers to T (ribothymidine or 5-methyluridine) and Ψ (pseudouridine) modifications of U54 and
U55, respectively, followed by C56. The Ψ55 is present
in nearly all tRNAs, again with the exception of eukaryotic
initiators and a few others. T or a further modification of T is
observed at position 54 in most bacterial and eukaryotic
tRNAs, but rarely in archaeal tRNAs. Most archaeal
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tRNAs, in contrast, especially those of Euryarchaeota, contain Ψ54 or a modified Ψ54 instead of T54 (Gupta 1984,
1985, 1986; Juhling et al. 2009; Blaby et al. 2011;
Chatterjee et al. 2012).
The tRNA methyltransferase TrmA/Trm2/TRMT2 and
tRNA Ψ synthase TruB/Pus4 produce T54 and Ψ55, respectively, in most bacterial and eukaryotic tRNAs (Ny
and Bjork 1980; Nurse et al. 1995; Becker et al. 1997a;
Nordlund et al. 2000). In Archaea, Pus10 can produce
both Ψ54 and Ψ55 (Gurha and Gupta 2008; Joardar
et al. 2013). Pus10 is distinct from the TruB family of Ψ synthases (Watanabe and Gray 2000; Mueller and FerreD’Amare 2009; Rintala-Dempsey and Kothe 2017). Those
Archaea that do have T54-containing tRNAs utilize an
ortholog of bacterial RumA, an rRNA methyltransferase, instead of the bacterial TrmA ortholog (Urbonavicius et al.
© 2021 Mukhopadhyay et al. This article is distributed exclusively by
the RNA Society for the first 12 months after the full-issue publication
date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml). After 12
months, it is available under a Creative Commons License
(Attribution-NonCommercial 4.0 International), as described at http://
creativecommons.org/licenses/by-nc/4.0/.
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2008). Pus10 produces only Ψ55 in these T54-containing
archaeal tRNAs (Roovers et al. 2006; Gurha and Gupta
2008; Joardar et al. 2013). Humans have two paralogs of
TruB, TRUB1, and TRUB2, that can produce Ψ55
(Zucchini et al. 2003; Rintala-Dempsey and Kothe 2017).
TRUB1 is present in both the nucleus and cytoplasm, but
its activity is predominantly in the nucleus (Safra et al.
2017). TRUB2 is present in the mitochondria and is suggested to produce Ψ55 in all four human mitochondrial
tRNAs (out of 22 total) with this modification (Suzuki and
Suzuki 2014; Antonicka et al. 2017). Humans also have
two paralogs of TrmA, TRMT2A, and TRMT2B, located in
the nucleus and mitochondria, respectively, that can produce T54 (Chang et al. 2019; de Crecy-Lagard et al. 2019).
Pus10 is present in most eukaryotes, but not in bacteria
and dikaryon fungi, including yeast (Watanabe and Gray
2000; Gurha and Gupta 2008; Fitzek et al. 2018). This coincides with the presence of Ψ54 instead of T54 in some
tRNAs of animals, such as tRNATrp and tRNAGln, and the absence of Ψ54 in the tRNAs of bacteria and yeast (Juhling
et al. 2009). Several Ψ54-containing tRNAs function as
primers in retroviral DNA synthesis (Mak and Kleiman
1997; Deogharia et al. 2019). Previously, we showed that
PUS10 produces Ψ54 in these tRNAs (Deogharia et al.
2019). Maximum Ψ54 activity was observed when the consensus sequence of the TΨC arm was GUUCAm1AAUC
(m1A is 1-methyladenosine and the underlined U is converted to Ψ54). Although human PUS10 is present in both
the nucleus and cytoplasm, it is the cytoplasmic PUS10
that produces Ψ54. The nuclear PUS10 is involved in apoptosis and translocates to the mitochondria in TRAIL-treated cells (Jana et al. 2017). Nuclear PUS10 is also involved in
miRNA processing and this activity is independent of tRNA
pseudouridylation by cytoplasmic PUS10 (Song et al.
2020). Crystal structure of human PUS10 shows that this
protein has two domains: an amino-terminal (Met1His285) THUMP-containing domain and a carboxy-terminal (Gly286–Asp528) Ψ synthase domain (McCleverty
et al. 2007). The carboxy-terminal domain has the full set
of conserved pseudouridine (Ψ) synthase active site residues. Structural alignment of human PUS10 and Pus10 of
Methanocaldococcus jannaschii, an archaeon, showed
nearly superimposable catalytic domains (Joardar et al.
2013). However, the amino-terminal domain of eukaryotic
Pus10 is much larger than that of archaeal Pus10
(McCleverty et al. 2007; Fitzek et al. 2018).
The presence of both TRUB and PUS10 in humans raises
the question of whether, in vivo, their Ψ55-synthase activities are redundant. We show here that all three human recombinant proteins, TRUB1, PUS10, and TRUB2, have
Ψ55 synthase activities, but differ slightly in their tRNA
structural requirements. These differences are specifically
reflected in the Ψ55 synthase activities of the nuclear, cytoplasmic, and mitochondrial extracts, respectively.
Furthermore, individual knockdown of TRUB1, PUS10,

and TRUB2 reduces the Ψ55 synthase activities of the nuclear, cytoplasmic, and mitochondrial extracts, respectively, suggesting compartmentalization of the activities of the
three proteins. The Ψ55 of tRNAs that contain T54Ψ55 are
produced by TRUB1 in the nucleus, but the two consecutive Ψs of the tRNAs that contain Ψ54Ψ55 are both produced by cytoplasmic PUS10. We also show that
catalytically inactive nuclear PUS10 specifically binds the
unmodified U54U55 versions of these Ψ54Ψ55-containing
tRNAs and inhibits TRUB1-mediated Ψ55 production in
these tRNAs in the nucleus. PUS10 binding can also explain
why U55 remains unmodified in initiator tRNA but Ψ55 appears in certain tRNAAla, although both tRNAs contain A54
and U55, and in vitro TRUB1 can modify U55 in both cases.

RESULTS
Recombinant human TRUB1, TRUB2, and PUS10
have tRNA Ψ55 synthase activities that depend
on specific structural requirements in tRNA
We showed previously that recombinant human PUS10
prepared from E. coli did not have any tRNA Ψ synthase activity, but that recombinant human PUS10 from SF9 insect
cells (called i-PUS10 here) did show both Ψ54 and Ψ55
synthase activities (Deogharia et al. 2019). In vitro, iPUS10 produced Ψ55 even in those tRNAs that are known
to have T54. Here, we used i-PUS10 and E. coli–derived recombinant TRUB1 and TRUB2 to compare their Ψ55 synthase activities. These activities were tested on [α-32P]
CTP-labeled transcripts of human tRNATrp and tRNAAla (sequences of tRNAs are shown in Supplemental Fig. S1),
which served as representatives of the tRNAs that normally
contain Ψ54 and T54, respectively. Both these tRNAs have
Ψ55. RNase T2 digests of the products showed radioactive
Ψp in all cases (Fig. 1A), suggesting that all three recombinant proteins can produce Ψ in both tRNA transcripts.
RNase T2 digests RNAs to ribonucleoside-3′ -monophosphates (Np). As a result, in this nearest-neighbor analysis,
the labeled 5′ -phosphate of the [α-32P]-labeled NTP
used to produce the transcript is transferred to the
3′ side of the preceding residue. Therefore, labeled U (or
modified U) spots in the RNase T2 digests of [α-32P]CTP-labeled transcripts would only be derived from the U of UC
sequences. Although UC is present in several places in the
transcripts, we believe that the Ψp observed in Figure 1A is
derived from U55, because TRUB1 and TRUB2 are known
to produce only Ψ55 and PUS10 only produces Ψ54 and
Ψ55 (Zucchini et al. 2003; Rintala-Dempsey and Kothe
2017; Deogharia et al. 2019).
Bacterial TruB and its yeast ortholog Pus4 require the
presence of U54 and A58, which form a reverse
Hoogsteen pair for their Ψ55 synthase activities (Becker
et al. 1997b; Gu et al. 1998). Therefore, we tested the requirements of these residues for all three human proteins
www.rnajournal.org
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by mutating U54 of tRNAAla to A, C, or G, and A58 to G
(Fig. 1B). Ψ55 was produced by TRUB1 in all cases.
TRUB2 and i-PUS10 did not produce any Ψ55 in these mutants. These results suggest that the Ψ55 activities of
TRUB2 and i-PUS10 depend on the presence of U54·A58
reverse Hoogsteen pair, but that of TRUB1 does not.
Eukaryotic initiator tRNAs (tRNAiMet) and several eukaryotic AGC anticodon-containing tRNAAla (called tRNAAU-Ala
here) contain A54 instead of U54 (see tRNAAla and tRNAAUAla
in Supplemental Fig. S1; Juhling et al. 2009; Westhof
et al. 2020). Although the U55 of human tRNAiMet remains
unmodified, that of tRNAAU-Ala is modified to Ψ in the cell
(Bunn and Mathews 1987; Juhling et al. 2009). Recombinant TRUB1 could produce Ψ55 in both of these tRNAs
(Fig. 1C), as was observed for the U54A mutant of tRNAAla
(Fig. 1B). This confirms that the Ψ55 activity of TRUB1 does
not specifically require U54. TRUB2 and i-PUS10 did not
produce Ψ55 in either of these two tRNAs (Fig. 1C), confirming that both proteins require U54 to produce Ψ55.
Previously, we showed that Ψ54 synthesis by i-PUS10
was substantially enhanced when the transcript contained
m1A58 (Deogharia et al. 2019). To determine whether Ψ55
synthesis by i-PUS10, TRUB1, and TRUB2 was also affected
by the presence of m1A58, we treated tRNATrp and
tRNAAla transcripts with TrmI to produce m1A58 as before
(Deogharia et al. 2019) and then treated them independently with the three proteins (Fig. 1D). Only TRUB2
showed increased Ψ55 production in the presence of
m1A58 (compare Fig. 1A with 1D). Unlike the Ψ54 activity
of i-PUS10, its Ψ55 activity was not affected by m1A58.
Overall these results suggest that unlike TRUB1, the Ψ55
activity of both i-PUS10 and TRUB2 requires the presence
of both U54 and A58. In addition, the m1A58 modification
enhances this activity, but only for TRUB2.

B

C

D

The tRNA Ψ55 synthase activities of nuclear,
cytoplasmic, and mitochondrial extracts are primarily
due to TRUB1, PUS10, and TRUB2, respectively

FIGURE 1. The tRNA Ψ55 synthase activities of recombinant proteins. Different [α-32P]CTP-labeled tRNA transcripts (indicated below
panels) were incubated with recombinant TRUB1, TRUB2, and iPUS10 (indicated above panels). Controls were untreated tRNAs.
Purified RNA products were digested with RNase T2, and the digests
were separated by 2D-TLC and phosphorimaged. As discussed in the
text, Ψ in all cases is derived from position 55 of the tRNAs. The mole
Ψ/mole tRNA ratio is indicated as a percentage in the panels where Ψ
is observed. Representative autoradiograms of repeat experiments
are shown. The labels indicate the 3′ -monophosphates of corresponding ribonucleosides. Inorganic phosphate is labeled as Pi, which is
cropped off in some panels. (A) Treatment of tRNATrp and tRNAAla.
(B) Treatment of U54 and A58 mutants of tRNAAla. (C) Treatment of
tRNAiMet and tRNAAU-Ala. (D) The tRNATrp and tRNAAla were first treated with TrmI to produce m1A58 and then treated with the three recombinant proteins.
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Nuclear, cytoplasmic, and mitochondrial extracts prepared from human PC3 cells produced Ψ in both tRNATrp
and tRNAAla (Fig. 2A). As shown later by knockdown of the
three proteins (Fig. 2C), most, if not all, of the Ψ produced
by the extracts is Ψ55. However, only the nuclear extract
produced Ψ55 with the U54A and A58G mutants of
tRNAAla (Fig. 2B). This was also the case with the recombinant TRUB1 (Fig 1B), which suggested that the Ψ55 synthase activity of TRUB1 is present in the nucleus.
To confirm the localization of the Ψ55 synthase activities
of the three proteins, we treated tRNATrp and tRNAAla with
the extracts of PC3 cells that had individual knockdowns
for each of the three protein genes, as well as the combined knockdown of all three genes. The Ψ55 synthase activities of the extracts were measured relative to Ψ27
synthesis in tRNAPhe mediated by PUS1 and PUS2 using
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the same nuclear and mitochondrial extracts and to Ψ31
synthesis in a mutant tRNAMet in the same cytoplasmic extracts. PUS1 and PUS2 are located in the nucleus and mitochondria, respectively (Rintala-Dempsey and Kothe 2017).
Pus6 is known to produce Ψ31 in tRNAs of both the cytoplasm and mitochondria in yeast (Ansmant et al. 2001) and
PUSD1 is suggested to do the same in human cells
(Spenkuch et al. 2014). The activities of PUS1, PUS2, and
tRNA Ψ31 synthase are not affected by knockdown of
TRUB1, TRUB2, and PUS10 (see Supplemental Methods
and Supplemental Fig. S2). Knockdown of TRUB1,
TRUB2, and PUS10 reduced Ψ55 synthesis by the nuclear,
mitochondrial, and cytoplasmic extracts, respectively, in
both tRNATrp and tRNAAla (Fig. 2C). Combined knockdown of all three genes reduced Ψ55 synthesis in all three
extracts. These results suggest that Ψ55 synthase activities
of TRUB1, TRUB2, and PUS10 are located in the nucleus,
mitochondria, and cytoplasm, respectively, and these
three proteins account for synthesis of tRNA Ψ55 in vivo.

The tRNA Ψ55 synthase activity of the nuclear
extract is not similar toward tRNATrp and tRNAAla

D

FIGURE 2. The tRNA Ψ55 synthase activities of TRUB1, PUS10, and
TRUB2 are mainly in the nucleus, cytoplasm, and mitochondria, respectively. (A) 2D-TLC analyses, as in Figure 1, after treating [α-32P]
CTP-labeled tRNATrp and tRNAAla with nuclear (NE), cytoplasmic
(CE), and mitochondrial (ME) extracts of PC3 cells. (B) 2D-TLC analyses
after treatment of U54A and A58G mutants of tRNAAla with NE and
CE. (C) Ratio of Ψ55 synthesis in tRNATrp and tRNAAla versus control
Ψ synthesis by NE, ME, and CE of PC3 strains individually knocked
down (KD) for TRUB1, TRUB2, and PUS10 and all three together (B1
+ B2 + P10). Untreated (WT) and luciferase siRNA-treated (siLuc) PC3
cells were used as controls. Control Ψ synthesis by the NE and ME
were PUS1- and PUS2-mediated Ψ27 synthesis in tRNAPhe and by
the CE was tRNA Ψ31 synthase-mediated Ψ31 synthesis in a mutant
tRNAMet, as described in the Supplemental Methods and
Supplemental Figure S2. Values are represented as mean ± SE. n = 2
replicates using independently prepared extracts. Each replicate is
presented as a scattered dot (filled circle). ANOVA with Sidak’s
Multiple comparison test with respect to the WT was performed and
significant P values for single KDs are presented as (∗ ) P < 0.05, (∗∗ )
P < 0.01, (∗∗∗ ) P < 0.001, and (∗∗∗∗ ) P < 0.0001. P values of all comparisons are shown in Supplemental Table S1. (D) 2D-TLC analyses, as in
A, after treating [α-32P]CTP-labeled tRNATrp and tRNAAla with 200 and
500 µg of NE and CE.

It is noteworthy that knockdown of both PUS10 and TRUB2
increased Ψ55 synthesis by the nuclear extract in tRNATrp,
but not in tRNAAla (Fig. 2C). Previously, we showed that
PUS10 produces Ψ54 in tRNATrp, but not in tRNAAla
(Deogharia et al. 2019). Furthermore, we also showed
that PUS10, although present mainly in the nucleus, has
its catalytic activity present in the cytoplasm (Jana et al.
2017; Deogharia et al. 2019). Therefore, we tested whether there would be a difference in Ψ55 production in
tRNATrp and tRNAAla by changing the amount of extracts
relative to the amount of tRNAs. As expected, more cytoplasmic extract increased PUS10-mediated Ψ55 synthesis
in both tRNATrp and tRNAAla (Fig. 2D). The same was observed for the activity of nuclear extract toward tRNAAla.
However, increased amount of nuclear extract decreased
Ψ55 synthesis in tRNATrp. This suggested that there is
some factor(s) in the nuclear extract that suppressed
TRUB1-mediated Ψ55 synthesis in tRNATrp but not in
tRNAAla. This factor(s) increased when the amount of nuclear extract increased relative to the tRNA in the experiments shown in Figure 2D. As shown later, nuclear
PUS10 is the factor that inhibits TRUB1-mediated Ψ55 formation in tRNATrp.

U54 and U55 of certain mammalian tRNAs are not
modified in the nucleus
The presence of Ψ55 synthase activities both in the nucleus and cytoplasm initially suggested that the two activities
are redundant and cytoplasmic PUS10 produces Ψ55 in
those tRNAs that for some reason escape TRUB1-mediated modification in the nucleus. An alternative explanation
www.rnajournal.org
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could be that Ψ55 is produced in one set of tRNAs by
TRUB1 in the nucleus and in another set by PUS10 in the
cytoplasm. Mammalian cells contain multiple isoacceptor
and isodecoder tRNAs for each amino acid. Therefore,
we tested whether a significant proportion of nuclear
tRNAs for certain amino acids in mouse liver cells contain
unmodified U55. We used primer extension after 1-cyclohexyl-3-(2-morpholinoethyl) carbodiimide metho-p-toluenesulfonate (CMCT) treatment of tRNA-enriched total
RNA isolated from nuclear and total cytoplasmic fractions
of mouse liver to determine the presence or absence of
Ψ (Fig. 3). CMCT forms adducts with Ψ, U, and G. Alkali removes all CMCT groups except those attached to N3 of Ψ.
Primer extension stops at one residue before the CMCTmodified Ψ. The tRNAAla and tRNAPhe, which normally
contain T54 and Ψ55, showed Ψ at position 55 for both nuclear and cytoplasmic tRNAs. The tRNAAU-ALA, which normally contains A54 and Ψ55, also showed Ψ at position 55
in the nucleus. These results suggest that Ψ55 is produced

in the nucleus in these tRNAs, before their transport to the
cytoplasm.
The tRNAGln and tRNATrp, which normally contain Ψ at
both position 54 and 55, showed Ψ at these positions in
the cytoplasmic fraction of tRNAs, but not in the nuclear
fraction. This suggested that both U54 and U55 in these
tRNAs remained unmodified in the nucleus and were converted to Ψ after transport to the cytoplasm. Treatment of
the nuclear RNA fraction with recombinant i-PUS10 produced Ψ at both positions in tRNATrp, confirming that nuclear tRNATrp indeed contains unmodified U54 and U55.
Had there been a T at position 54, it could not have
been converted to Ψ. Since tRNAiMet normally contains unmodified U55, we used total cellular RNA. As expected, no
Ψ55 was observed in this case. Recombinant TRUB1 treatment of total RNA produced Ψ55 in tRNAiMet, confirming
that the U55 of this tRNA normally remains unmodified in
the cell.

Cytoplasmic PUS10 can produce Ψ, but nuclear
PUS10 cannot

FIGURE 3. CMCT-primer extension analyses to determine the presence of Ψ55 in certain tRNAs in the nucleus and cytoplasm. The
tRNA-enriched total RNAs prepared from the nuclear (N) and total cytoplasmic (C) extracts of mouse liver were first treated with AlkB to
demethylate m1A58, which improves primer extension. These RNAs
were either not treated (−) or treated with CMCT (+) for 20 min, followed by alkali treatment before primer extension reactions. The sequence of each primer for the tRNA of a particular amino acid
corresponds to the 15 bases at position 62–76 of one isoacceptor
for that amino acid (indicated below the panels). A dark band in the
CMCT lane but not in the untreated lane indicates a Ψ. Dark bands
in both lanes at the same position are caused by inhibition of primer
extension by the presence of a modified residue at that position or
due to a strong secondary and/or tertiary structure in that region.
Unmodified U (and the T54 of tRNA) does not produce a dark band
in either lane. The position of the band in the gel that corresponds
to Ψ is determined by its distance from the end of the primer and correlation with the known sequence of the RNA. The asterisk next to a
band indicates the presence of Ψ at that position. Positions 54 and
55 are indicated on the side. Reactions for tRNAAU-Ala were done
only with the nuclear RNA. Reactions for tRNAiMet were done with
the RNA isolated from total cell extract. The i-PUS10 treatment of nuclear RNA before the CMCT reaction converted both U54 and U55 of
its tRNATrp to Ψ54 and Ψ55. Similarly, U55 of tRNAiMet, when treated
with TRUB1 before the CMCT reaction was converted to Ψ55.
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Previously using an anti-PUS10 antibody, we showed that
PUS10 is mainly present in the nucleus (Jana et al. 2017;
Deogharia et al. 2019). However, PUS10-mediated Ψ54
formation in select tRNAs (tRNATrp and tRNAGln but not
in some others, for example, tRNAAla and tRNAPhe) was observed only in the cytoplasmic extracts, not in the nuclear
extracts (Deogharia et al. 2019). Unlike Ψ54 synthesis,
PUS10 could produce Ψ55 in both tRNATrp and tRNAAla,
and this activity too is cytoplasmic (Fig. 2). Although distinct, the nuclear and cytoplasmic versions of PUS10 are
products of a single gene, not paralogous genes (Fitzek
et al. 2018). This was confirmed when anti-His antibody
could detect His-tagged PUS10 overexpressed from a
plasmid-borne copy of PUS10, both in the nucleus and cytoplasm of HEK293T cells (Deogharia et al. 2019).
Therefore, we ascertained whether recombinant human
PUS10 isolated from HEK293T cells also had Ψ synthase activity, and whether there was any difference between the
recombinant PUS10 from the nuclear and cytoplasmic extracts. Here we refer to recombinant PUS10 proteins prepared from total cell, nuclear, and cytoplasmic extracts of
HEK293T cells as h-PUS10, nh-PUS10, and ch-PUS10, respectively. Ψ55 synthesis was observed with ch-PUS10 in
both tRNATrp and tRNAAla (Fig. 4A), although not as robust
as with i-PUS10 (Fig. 1A). No Ψ55 was observed with either
h-PUS10 or nh-PUS10 (Fig. 4A). We also confirmed that chPUS10 has Ψ54 synthase activity similar to that of i-PUS10,
that is, it produces Ψ54 in tRNATrp, but not in tRNAAla, but
again the activity was much less than that of i-PUS10 (Fig.
4B). Ψ54 synthesis was determined by nearest-neighbor
analysis using [α-32P]UTP-labeled m1A58-modified
tRNAs, as was done before (Deogharia et al. 2019). These
results suggest that although recombinant cytoplasmic
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tRNATrp or tRNAGln, and even by tRNAiMet at a higher concentration, but not by tRNAPhe (Fig. 5D). We also observed that it
is only the nuclear fraction (nh-PUS10) that binds to these
tRNAs, not the cytoplasmic fraction (ch-PUS10) (Fig. 5E).
Overall, these results suggest that catalytically inactive
nuclear PUS10, which is the major fraction of total
PUS10, binds to tRNAs that contain AAAU (or GAAA) at
position 57–60, whereas catalytically active cytoplasmic
PUS10 (and i-PUS10) does not bind under the EMSA conditions we tested. Probably the latter binds transiently to
the tRNA during catalysis and dissociates after that.

Stably bound PUS10 blocks Ψ55 synthesis

FIGURE 4. Cytoplasmic PUS10 has Ψ synthase activity. (A) Ψ55 synthase activities of h-PUS10, nh-PUS10, and ch-PUS10 were determined by 2D-TLC analyses as in Figure 1, after using these proteins
to treat [α-32P]CTP-labeled tRNATrp and tRNAAla. (B) Ψ54 synthase activities of ch-PUS10 and i-PUS10 were determined by 2D-TLC analyses as in Figure 1, after using these proteins to treat [α-32P]UTPlabeled tRNATrp and tRNAAla. The tRNAs were pretreated with TrmI
to produce m1A58, which enhances Ψ54 synthesis by PUS10.

PUS10 is weakly catalytic, PUS10 isolated from total cell extract does not show any activity, because catalytically inactive nuclear PUS10 is its major component.

Nuclear PUS10 binds some but not all tRNAs
Previously, we showed that the AAAU sequence at positions 57–60, which is present in tRNATrp and tRNAGln, but
not in tRNAAla and tRNAPhe, is needed for the Ψ54 synthase
activity of i-PUS10 (Deogharia et al. 2019). Therefore, we
tested whether h-PUS10 or i-Pus10 can bind to any tRNA.
The h-PUS10 binds to tRNATrp and tRNAGln, but not to
tRNAAla and tRNAPhe under our EMSA conditions (Fig.
5A). However, the i-PUS10 does not bind either to
tRNATrp or to tRNAAla under the same conditions (Fig.
5B). The h-PUS10 also binds to tRNAiMet, although at higher concentrations than to tRNATrp (Fig. 5C), which may be
due to the presence of GAAA in tRNAiMet, instead of
AAAU at position 57–60. The h-PUS10 does not bind to
tRNAAU-Ala (Fig. 5C), which has GAUG at position 57–60.
We mutated AA at positions 59–60 of tRNAiMet to UG
to make the sequence GAUG at position 57–60, as in
tRNAAU-Ala, and did the reverse mutation in tRNAAU-Ala to
make it like tRNAiMet. Now h-PUS10 binds to mutated
tRNAAU-Ala but not to mutated tRNAiMet (Fig. 5C). The
binding of h-PUS10 to tRNATrp is specific, because it
could be competed out by addition of excess unlabeled

Since nuclear h-PUS10 can stably bind certain tRNAs, we
wanted to ascertain whether this binding blocks Ψ55 synthesis by TRUB1. We first bound recombinant h-PUS10 to
different tRNAs and then compared recombinant TRUB1mediated Ψ55 synthesis in these tRNAs with corresponding unbound tRNAs. As expected, Ψ55 synthesis was
decreased in the tRNAs (tRNATrp and tRNAiMet) to which
h-PUS10 binds, but not in the tRNAs (tRNAAla and
tRNAAU-Ala) to which it does not bind (Fig. 6A).
Although recombinant TRUB1 can produce Ψ55 both in
tRNAiMet and tRNAAU-Ala (Figs. 1C and 6A), the former normally contains unmodified U55, whereas the latter has Ψ55
in the cell. Therefore, we tested the activities of nuclear
and cytoplasmic extracts on these tRNAs, as done for
tRNATrp and tRNAAla in Figure 2A. (Mitochondrial extract
was not used with these tRNAs, because no human mitochondrial tRNA has AU at positions 54–55.) Under our normal reaction conditions (as used in Fig. 2), tRNAAU-Ala
showed Ψ55 synthesis only with the nuclear extract, but
neither extract produced Ψ55 in tRNAiMet (Fig. 6B). As expected, an AA to GU mutant of tRNAiMet (same mutant as
used in Fig. 5C) recovered the nuclear Ψ55 activity, and the
reverse change in tRNAAU-Ala lost it (Fig. 6B).
The absence of Ψ55 synthesis in tRNAiMet by the nuclear
extract was not expected, because recombinant TRUB1
could produce Ψ55 in this tRNA (Fig. 1C). We hypothesized that the PUS10 present in the nuclear extract bound
to tRNAiMet and did not allow TRUB1 to act. Therefore, to
saturate the PUS10, we added excess unlabeled tRNAiMet
to the nuclear extract reactions of tRNAiMet and mutant
tRNAAU-Ala, that did not show Ψ55 synthesis. In both cases,
Ψ55 formation was recovered (Fig. 6B).
To confirm that it is the nuclear PUS10, and not the cytoplasmic PUS10 that inhibits Ψ55 synthase activities of the
extracts, we first independently treated tRNATrp and
tRNAAla with recombinant nh-PUS10 and ch-PUS10. We
then determined Ψ55 synthesis in these tRNAs, separately
using nuclear and cytoplasmic extracts (Fig. 6C). As expected, in the case of tRNATrp, stable nh-PUS10 binding
significantly reduced the activities of both nuclear and cytoplasmic extracts. Since nh-PUS10 does not bind to
www.rnajournal.org
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A

B

D

C

E

FIGURE 5. Catalytically inactive PUS10 selectively binds only certain other tRNAs. (A) Radiolabeled tRNAs for Trp, Gln, Ala, and Phe (indicated
below the panels) were incubated with increasing concentrations of h-PUS10, resolved by native PAGE, and visualized by phosphorimaging.
(B) Reactions similar to those in A using i-PUS10 with tRNATrp and tRNAAla. (C) Reactions similar to those in A using h-PUS10 with tRNAiMet
and tRNAAU-Ala and their mutants (mut-iMet and mut-AU-Ala) where sequences at positions 59–60 were interchanged as described in the
text. (D) Separately radiolabeled tRNATrp (∗ Trp) along with increasing concentrations of unlabeled tRNAs (indicated above the panels) for Trp,
Gln, initiator Met, and Phe were incubated with h-PUS (20 µM), resolved by native PAGE, and visualized by phosphorimaging. The first lane in
each panel contains only the radiolabeled tRNATrp, with no unlabeled tRNA or h-PUS10. (E) Reactions similar to A after separate incubations
of tRNATrp with nh-PUS10 and ch-PUS10.
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A

B

tRNAAla, there was hardly any effect
on its Ψ55 synthesis by either extract.
On the other hand, the addition of chPUS10 increased Ψ55 synthesis in
both tRNAs by both extracts, because
ch-PUS10 provides additional Ψ55
synthesizing capability.
Overall, these results suggest that
nuclear PUS10 inhibits the activity of
TRUB1 in the nucleus by binding to
those tRNAs, for example, tRNATrp
and tRNAGln, that contain the sequence 57-AAAU-60 (or its variant
GAAA in tRNAiMet). Although stable
binding of nuclear PUS10 to tRNATrp
is also capable of inhibiting cytoplasmic PUS10, this does not occur
normally in the cell. These results
can also explain why knockdown of
PUS10 increases TRUB1-mediated nuclear Ψ55 synthesis in tRNATrp (Fig.
2C), where the amount of PUS10 is decreased in nuclear extract. Similarly,
increased amount of nuclear extract
relative to tRNA decreases TRUB1mediated Ψ55 synthesis in tRNATrp
(Fig. 2D), because the amount of
PUS10 relative to tRNA is increased.

DISCUSSION
C

FIGURE 6. Bound PUS10 blocks Ψ55 synthesis. (A) Activity of recombinant TRUB1 was determined as in Figure 1A, using different [α-32P]CTP-labeled tRNAs (indicated below the panels),
with or without pretreating the tRNAs with h-PUS10. Values are represented as mean ± SE. n =
3 replicates. Each replicate is presented as a scattered dot. ANOVA with Sidak’s Multiple comparison test with respect to the “+TRUB1” was performed and significant P values are presented as (∗ ) P < 0.05 and (∗∗ ) P < 0.01. P values of all comparisons are shown in Supplemental Table
S1. (B) Activity of nuclear (NE) and cytoplasmic (CE) extracts were determined as in Figure 2A
using [α-32P]CTP-labeled tRNAiMet and tRNAAU-Ala and their interchanged mutants (same as in
Fig. 5C). In separate NE reactions with tRNAiMet and mut-AU-Ala, extra unlabeled tRNAiMet (extreme right panels) was added to saturate the PUS10 present in the extract. (C) Activities of NE
and CE were determined as in A, using [α-32P]CTP-labeled tRNATrp and tRNAAla, with or without pretreating the tRNAs with ch-PUS10 or nh-PUS10. Values are represented as mean ± SE.
n = 2 replicates using independently prepared extracts. Each replicate is presented as a scattered dot. ANOVA with Sidak’s Multiple comparison test with respect to the NE or CE, as appropriate, was performed and significant P values are presented as (∗ ) P < 0.05 and (∗∗ ) P < 0.01.
P values of all comparisons are shown in Supplemental Table S1.

We show here that although both
mammalian TRUB1 and PUS10 can
produce Ψ55 in U54U55-containing
tRNAs in vitro, their activities inside
the cell are compartmentalized and
they modify different sets of tRNAs.
TRUB1 primarily produces Ψ55 in the
nucleus in those tRNAs that normally
contain T54 and PUS10 produces
Ψ55 in the cytoplasm in those tRNAs
that normally contain Ψ54. Previously
we showed that there are two versions
of PUS10, nuclear and cytoplasmic
(Jana et al. 2017; Deogharia et al.
2019). The nuclear version is noncatalytic and is involved in TRAIL-induced
apoptosis, while the catalytic cytoplasmic version produces Ψ54. Here
we show that nuclear PUS10 stably
binds to unmodified U54U55 version
of Ψ54-containing tRNAs and inhibits
TRUB1-mediated Ψ55 production in
these tRNAs. Both Ψ54 and Ψ55 are
produced by the cytoplasmic PUS10
www.rnajournal.org
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in these tRNAs. Specific binding of nuclear PUS10 to select
tRNAs can also explain the absence of Ψ55 in tRNAiMet and
its presence in tRNAAU-Ala.
Nuclear extracts do produce Ψ55 in both tRNATrp and
tRNAAla (Fig. 2A), and TRUB1 knockdown reduces Ψ55 in
both these tRNAs (Fig. 2C). These results suggest that
TRUB1 activity is not affected by nuclear PUS10.
However, increasing nuclear extract to tRNA ratio increases
Ψ55 synthesis in tRNAAla, but decreases it in tRNATrp (Fig
2D), suggesting that nuclear PUS10 does decrease
TRUB1 activity toward tRNATrp. We believe that the reason
for these contradictory results is that only a limited amount
of free PUS10 is available in the nuclear extract, which can
bind only a small amount of added labeled tRNATrp. TRUB1
of the extract can then act on the remaining unbound
tRNATrp as observed in Figure 2A. When the amount of
the extract is increased, more tRNATrp becomes bound to
PUS10 and less tRNATrp is available for TRUB1 to act on,
as observed in Figure 2D. In case of knockdown of
TRUB1, less TRUB1 would be available to act on both
tRNAAla and unbound tRNATrp, decreasing Ψ55 synthesis
in both tRNAs as seen in Figure 2C.
It is intriguing that TRUB2 knockdown increases Ψ55
synthesis by PUS10 of the cytoplasmic extract in both
tRNATrp and tRNAAla, but only in tRNATrp by TRUB1 of
the nuclear extract (Fig. 2C). It seems that somehow
TRUB2 knockdown decreases the amount of PUS10 in
the nucleus and increases it in the cytoplasm. A decrease
of nuclear PUS10 would increase the amount of unbound
tRNATrp, thus increase Ψ55 in this tRNA, and an increase
of cytoplasmic PUS10 would increase Ψ55 in both
tRNAs. TRUB2 may have an effect on the nuclear-cytoplasmic distribution of PUS10.
The dichotomy of activities between nuclear and cytoplasmic PUS10 has also been reported recently by others
(Song et al. 2020). They showed that nuclear PUS10 is involved in miRNA processing, and, as here, cytoplasmic
PUS10 catalyzes tRNA pseudouridylation. Their results
agree with ours in some respects and differ in others.
They observed that recombinant human PUS10 isolated
from E. coli can both bind to several classes of RNAs and
produce Ψ in tRNAs. As reported before, our E. coli–derived human PUS10 did not show any catalytic activity
(Deogharia et al. 2019). Unlike their protein, our catalytic
proteins (i-PUS10 and ch-PUS10) did not show binding to
any tRNA under our EMSA conditions. Probably these proteins transiently bind during catalysis.
They used demethylase-pseudouridine sequencing to
determine Ψ54 and Ψ55 production by PUS10 in natural
tRNAs by comparing the Ψ’s at these sites in the wildtype and PUS10 knockout (KO) cells. They concluded
that PUS10 produces Ψ55 in an AGC anticodon-containing tRNAAla that has A54 instead of U54 (its TΨC loop is
identical to our tRNAAU-Ala). However, as shown in
Figures 1C and 6B, Ψ55 in tRNAAU-Ala can be produced
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by both recombinant TRUB1 and nuclear extract, but neither by recombinant PUS10 nor by cytoplasmic extract,
because PUS10 cannot produce Ψ55 in the presence of
A54. Furthermore, Ψ55 is observed in this tRNA in the nucleus (Fig. 3), again suggesting it is synthesized by TRUB1
inside the cell. They observed the absence of Ψ54 in select
tRNAs (e.g., tRNATrp, tRNAGln, etc.) and the presence of
Ψ55 in these tRNAs in the KO cells. Therefore, they assigned the production of Ψ54 but not of Ψ55 to PUS10
in these tRNAs. We believe that even Ψ55 in these
tRNAs is normally produced by PUS10 in the cytoplasm,
because we showed that stable binding of noncatalytic nuclear PUS10 to these tRNAs normally inhibits TRUB1-mediated Ψ55 in these tRNAs. We interpret their data
differently. Both Ψ54 and Ψ55 in these tRNAs are produced by the cytoplasmic PUS10 under normal conditions.
However, the absence of PUS10 in their KO cells allows nuclear TRUB1 to access these tRNAs and produce Ψ55.
Although PUS10 can produce both Ψ54 and Ψ55, the
two activities show some differences. It can produce Ψ54
in select tRNAs that have a consensus AAAU sequence at
position 57–60 and m1A58 modification enhances this activity (Deogharia et al. 2019). Its Ψ55 synthesis shows no
such preference, but does require U at position 54. The
catalytic activity of ch-PUS10 is much weaker than that of
i-PUS10. There may be some structural or posttranslational
differences between the two recombinant proteins. Also,
there may be some associated factor(s) that are required
to enhance the activity of PUS10 in the cytoplasm.
Both mammalian and yeast tRNAiMet have unmodified
U55 and A54. An ortholog of TruB, Pus4 is present in yeast
and is responsible for Ψ55 synthesis in both cytoplasmic
and mitochondrial tRNAs (Becker et al. 1997a). Pus4 requires the presence of U54 in the tRNA for its activity and
thus cannot produce Ψ55 in yeast tRNAiMet (Becker et al.
1997b). The reason for the absence of Ψ55 in mammalian
tRNAiMet is different. Although mammalian TRUB1, unlike
PUS10, does not require U54 in the tRNA for Ψ55 synthesis
and can produce Ψ55 in tRNAiMet in vitro, it is blocked
because the tRNA is bound by PUS10 in the nucleus.
TRUB1 is reported to be present in both nucleus and cytoplasm, but its activity is predominantly in the nucleus (Safra
et al. 2017). This may be the reason that cytoplasmic TRUB1
may not be able to produce Ψ55 in mammalian tRNAiMet
even after its transport to the cytoplasm.
It is possible that nuclear PUS10 binding to select
tRNAs, in addition to inhibiting TRUB1, also inhibits
TRMT2A-mediated T54 synthesis in the nucleus in these
tRNAs. TRMT2A is mainly observed in the nucleus in
HeLa cells (Chang et al. 2019), and in yeast T54 is synthesized after Ψ55 (Barraud et al. 2019). Therefore, neither
U54 nor U55 of the tRNAs to which PUS10 binds, is modified in the nucleus. We believe that the tRNATrp and
tRNAGln in the KO cells of Song and colleagues (Song
et al. 2020) would have T54Ψ55 instead of normal
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Ψ54Ψ55 due to the absence of PUS10, as is the case for
yeast cells, which do not have PUS10.
We isolated two versions of recombinant human PUS10
from HEK293T cells: a nuclear and a cytoplasmic version.
This suggested that there is a nuclear and a cytoplasmic
isoform of PUS10 in human cells. The nuclear isoform is
catalytically inactive and can stably bind to tRNATrp.
Recombinant protein isolated from total extract of
HEK293T cells behaves like nuclear isoform, suggesting
nuclear isoform is the major component of the total protein. Nuclear isoform is also shown to be involved in
TRAIL-induced apoptosis and miRNA processing (Jana
et al. 2017; Song et al. 2020). On the other hand, cytoplasmic isoform is catalytically active and does not stably bind
tRNATrp. Although both isoforms are of the same size
(Supplemental Fig. S3B) and are products of the same single gene (Fitzek et al. 2018), the two probably differ in their
structure or in posttranslational modifications. The two
PUS10 isoforms are distinct because the addition of nuclear extract to cytoplasmic extract does not alter PUS10-mediated Ψ54 synthase activity of the latter (Deogharia et al.
2019). In principle, the two isoforms could be splice variants of the same gene product. However, based on the
available information (https://www.proteinatlas.org/ENS
G00000162927-PUS10/cell#human and http://useast
.ensembl.org/Homo_sapiens/Transcript/ProteinSummary
?db=core;g=ENSG00000162927;r=2:60940222-610182
59;t=ENST00000421319), this is less likely. Human PUS10
is suggested to have six splice variants. Of these, only four
are protein coding, two of which give rise to annotated fulllength PUS10 (529 aa), and the other two are expected
to produce proteins of 62 aa and 120 aa. The latter two
shorter versions do not contain the catalytic domain
(McCleverty et al. 2007) of the protein. Human Pus10
splice variants that code for the 529 aa protein contain
18 exons. Conversion of the same PUS10 gene product
into two isoforms appears to occur in mammalian cells
but not in insect cells, because recombinant human
PUS10 isolated from SF9 cells behaves only like human cytoplasmic isoform (i.e., it has catalytic activity and does not
stably bind tRNATrp). Although the insect Pus10 gene has a
nuclear localization signal, so far there is no report of any
catalytic or noncatalytic function assigned to insect nuclear
or cytoplasmic Pus10 and roles of PUS10 and TRUB in
tRNA Ψ55 synthesis.
There appears to be some association between Ψ54
modification of tRNA and retroviral DNA synthesis.
Several Ψ54-containing tRNAs function as primers for the
retroviral reverse transcriptases (Mak and Kleiman 1997;
Deogharia et al. 2019). Interaction of avian and mammalian tRNATrp with avian myeloblastosis virus reverse transcriptase either requires or is stabilized by Ψ at positions
54 and 55 (Hu and Dahlberg 1983). Although tRNALys3,
the primer for HIV reverse transcriptase, is reported to contain 2′ -O-methylribothymidine (Tm) at position 54 (Juhling

et al. 2009), we showed previously that human PUS10 can
produce Ψ54 in this tRNA (Deogharia et al. 2019).
Therefore, it may be worth investigating whether PUS10
knockout cells, where Ψ54Ψ55 in the tRNAs would be replaced by T54Ψ55 are resistant to infection by retroviruses
and to transduction by lentiviral vectors.
Based on this work, compartmentalization of Ψ55 synthesis between the nucleus and cytoplasm is diagrammatically presented in Figure 7. TRUB1 produces Ψ55 in most
U54U55-containing tRNAs, for example, tRNAAla and
tRNAPhe, and A54U55-containing elongator tRNAs, for example, tRNAAU-Ala in the nucleus, and then these tRNAs
are exported to the cytoplasm. Nuclear PUS10 (nhPUS10) inhibits nuclear TRUB1 activity by binding to a specific set of U54U55-containing tRNAs, for example,
tRNATrp, tRNAGln, that have the consensus sequence
AAAU at position 57–60. These tRNAs are exported to
the cytoplasm with both U55 and U54 unmodified.
Cytoplasmic PUS10 (ch-PUS10) produces both Ψ54 and
Ψ55 in these tRNAs. Nuclear PUS10 also binds to
tRNAiMet, which has A54U55 and GAAA at position 57–
60 and inhibits its U55 to Ψ55 conversion by nuclear
TRUB1. However, U55 of tRNAiMet remains unmodified

FIGURE 7. Overview of Ψ55 synthesis in different tRNAs. TRUB1 produces Ψ55 in U54U55-containing tRNAAla and A54U55-containing
tRNAAU-Ala in the nucleus. Modified tRNAs are then exported to the
cytoplasm. Conversion of U54 to T54 in tRNAAla is not shown here.
Nuclear PUS10 (nh-PUS10) inhibits nuclear TRUB1 activity by binding
to U54U55-containing tRNATrp that has AAAU at position 57–60, and
to A54U55-containing tRNAiMet, that has GAAA at position 57–60.
These tRNAs are consequently exported to the cytoplasm with an unmodified U55. Cytoplasmic PUS10 (ch-PUS10) produces both Ψ54
and Ψ55 in tRNATrp, but not in tRNAiMet.
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even in the cytoplasm because PUS10 cannot produce
Ψ55 in those tRNAs that contain A54.
This work raises a question. How is the catalytically inactive Pus10 replaced by the active Pus10 in the cytoplasm?
A possibility is that it dissociates during nucleus to cytoplasm transport of tRNAs. Nuclear PUS10 remains in the
nucleus and free cytoplasmic PUS10 produces Ψ54 and
Ψ55 in the tRNAs. An alternative possibility is that the noncatalytic nuclear PUS10-bound tRNAs are exported to the
cytoplasm, where some structural change in the bound
PUS10 converts it into catalytic PUS10. This change can occur either while crossing the nuclear membrane or after
reaching the cytoplasm. The catalytic PUS10 after producing Ψ54 and Ψ55 dissociates from the tRNA. Since we observed that unless overexpressed, normal PUS10 is
detected only in the nucleus and not in the cytoplasm, it
is possible that after release from the tRNA most of the cytoplasmic PUS10 is either degraded or transported back to
the nucleus.
Unanswered basic questions still remain: Why are
U54U55 of most but not all mammalian tRNAs converted
to T54Ψ55 by two different enzymes (TRUB1 and
TRMT2a) in the nucleus, and why are the same Us of certain
other tRNAs protected by another protein (PUS10) from
these two nuclear enzymes, transported to the cytoplasm,
and there converted to Ψ54Ψ55 by the catalytic version of
the same protein? Further studies are needed to answer
these questions.

MATERIALS AND METHODS
Standard molecular biology procedures (Green and Sambrook
2012) were used unless specifically described. Oligonucleotides
used in this work are listed in Supplemental Table S2.

Cell cultures
PC3 cells were cultured in RPMI 1640 (ATCC), and HEK293T cells
were grown in DMEM media (HyClone, GE Healthcare), both with
10% FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin
(15140122, Gibco, Thermo Fisher) under standard culture conditions (37°C and 5% CO2).

Preparation of recombinant proteins and assays
Recombinant human PUS10 from SF9 insect cells (i-PUS10) was
prepared and used for reactions as described before
(Deogharia et al. 2019). Recombinant human PUS10 proteins
from HEK293T cells were prepared by using PUS10 gene in a
clone in pEF6/V5-His-TOPO (Invitrogen) described before
(Deogharia et al. 2019), to transiently transfect the cells using
TurboFect (Thermo Fisher). The cells were harvested after 48 h incubation. Total cell extracts from these cells were prepared as described before (Deogharia et al. 2019). Recombinant protein
(h-PUS10) from the total cell extract was purified using an NiNTA column and used for the reactions as described before for
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i-PUS10 (Deogharia et al. 2019). Although PUS10 is not normally
detected in the immunoblots of WT cytoplasmic extracts, overexpressed His-tagged PUS10 protein is detectable in these extracts
(Deogharia et al. 2019). Therefore, recombinant nuclear (nhPUS10) and cytoplasmic (ch-PUS10) PUS10 proteins were also
prepared from the nuclear and total cytoplasmic fractions of total
cell extract (Supplemental Fig. S3B). The fractions were prepared
as described before (Jana et al. 2017). The purity of these and other subcellular fractions described later was determined by immunoblotting using antibodies against appropriate markers. These
are shown in Supplemental Figure S3.
To clone human TRUB1 and TRUB2 genes, cDNA was prepared
first from the total RNA of HEK293T cells using the Superscript III
First Strand Synthesis System for RT-PCR kit with oligo dT primers
(Invitrogen). TRUB1 and TRUB2 were amplified from the cDNA using primers corresponding to their coding regions. The resulting
PCR product for TRUB1 was cloned between the NcoI and XhoI
sites of the pET28a vector (Novagen, EMD Millipore). TRUB2
was cloned between the XbaI and XhoI sites of the same vector.
E. coli BL21 (DE3) pLysS cells (Novagen) were transformed with
these clones and grown to an O.D600 of 0.5 and induced with 1
mM IPTG for 2 h at 37°C. After harvesting, the cells were used
for protein purification using an Ni-NTA column as previously
mentioned.
Concentrations of recombinant proteins were determined by
the Coomassie Protein Assay reagent (Thermo Scientific
1856209). Reaction conditions were similar to those used for
the i-PUS10 protein (Deogharia et al. 2019). Reactions contained
4 pmol tRNA and 50 µg protein (∼600 pmol of PUS10 proteins or
approximately 1 nmol of TRUB proteins) in a 50 µL volume. Some
reactions with TRUB1 were done after pretreating 4 pmol of a
tRNA with 50 µg h-PUS10.
TrmI and AlkB were purified and used as described before
(Deogharia et al. 2019).

Preparation of tRNA transcripts
Cloned genes of tRNATrp, tRNAAla, tRNAPhe, and tRNAGln were
used to prepare transcripts as described before (Deogharia
et al. 2019). Transcripts for tRNAiMet, tRNAAU-Ala, and tRNAMet
were prepared from the PCR-amplified DNAs using two primers
that overlapped at their 3′ -end. Forward primers for all PCR contained T7 RNA polymerase promoter sequences. PCR primers
containing the desired mutations were used to prepare mutant
tRNAs. In vitro transcriptions to prepare 32P-labeled and unlabeled transcripts were carried out as described before (Gurha
et al. 2007; Gurha and Gupta 2008).

Pseudouridylation detection by thin layer
chromatography
Reaction products of 32P-labeled tRNAs treated with recombinant
proteins or cellular fractions were phenol–chloroform extracted,
ethanol precipitated, and digested with RNase T2. The digests
were resolved by two-dimensional TLC on cellulose plates
(EMD Millipore). The solvents used were Solvent I (isobutyric
acid/0.5 N NH4OH, 5:3, v/v) for the first dimension and Solvent
II (isopropanol/HCl/H2O, 70:15:15, v/v/v) for the second dimension (Gupta 1984; Gurha et al. 2007; Gurha and Gupta 2008).
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Radioactivity in the plates was revealed and quantified by phosphorimaging using Optiquant software. All assays were repeated
at least twice. The mole Ψ/mole RNA was determined by the formula (radioactivity in Ψp spot × the number of labeled nucleotides per transcript)/(sum of the radioactivity in all Np spots).
This number was multiplied by 100 to determine percent Ψ produced. We could detect as low as 1% pseudouridylation in our
TLC assays. We prepared RNase T2 according to a published procedure (Lichtler et al. 1992). These preparations contained some
phosphatase activity. Since this activity nonspecifically removed
phosphate (Pi) from all nucleotides, we did not include radioactivity in the Pi spot in calculating mole Ψ/mole RNA.

Determination of pseudouridylation activity
of subcellular fractions
Nuclear, cytoplasmic, and mitochondrial extracts of PC3 cells
were prepared according to a published procedure (Dewe et al.
2017). Briefly, cells from 100 cm tissue culture plates were harvested after trypsinization, washed twice with PBS (137 mM NaCl, 27
mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4), and resuspended in
3–5 mL homogenization buffer (10 mM Tris-HCl, pH 6.7, 10 mM
KCl, 0.15 mM MgCl2, 1 mM PMSF, and 1 mM DTT) per plate.
The suspension was lysed with 40 strokes of a Dounce homogenizer and then transferred to a 15-mL conical tube. An appropriate
amount of concentrated sucrose solution in homogenization buffer was added to bring the final sucrose concentration to 0.25
M. The suspension was centrifuged at 1000g for 5 min in a swinging-bucket rotor at 4°C to pellet nuclei. The supernatant was
transferred to a fresh tube and centrifuged at 5000g at 4°C for
10 min in a fixed-angle rotor to pellet mitochondria. The pellet
containing mitochondria was washed with sucrose-containing
buffer (10 mM Tris-HCl, pH 6.7, 0.15 mM MgCl2, 0.25 M sucrose,
1 mM PMSF, 1 mM DTT). The supernatant was saved as the cytoplasmic extract. The mitochondrial and nuclear pellets were resuspended in PBS containing 0.1% NP40 and protease inhibitor
cocktail (Pierce) and sonicated three times for 3–5 s at 3 watts
each, to prepare the nuclear and mitochondrial extracts, respectively. Protein concentrations of the extracts were determined
by the Coomassie Protein Assay reagent. Activities of the extracts
were determined as described before (Deogharia et al. 2019), except that 100 µg (protein) of mitochondrial extract was used in
each reaction instead of 200 µg, as used for the nuclear and cytoplasmic extracts. Some reactions with nuclear and cytoplasmic extracts were done after pretreating 4 pmol of a tRNA with 50 µg nhPUS10 or ch-PUS10. Each reaction was done twice using two independently prepared extracts.

Preparation of knockdown cells
siRNAs were used for transient knockdown of TRUB1 and TRUB2
in PC3 cells. The siRNA for each gene was designed using the
server (http://sirna.wi.mit.edu/). These are listed in Supplemental
Table S2. Sense and antisense strands were hybridized at 95°C for
5 min followed by slow cooling to 25°C to create a duplex and
then placed on ice for 10 min. The transfections using jetPRIME
transfection reagent (Polypus) were performed as recommended
by the manufacturer. The cells were harvested 72 h posttransfection and assayed for the gene of interest using immunoblotting

and qPCR as described before (Jana et al. 2017; Deogharia
et al. 2019). The data are shown in Supplemental Figure S4.
Image J was used for densitometric analysis of the immunoblots
and the values obtained relative to the WT PC3 cells are represented as fold change.
PUS10 knockdown strain KD1 of PC3 cells prepared before
(Jana et al. 2017) was used here to study the effect of reduction
of PUS10. We could not produce an shRNA-mediated PC3 strain
that had a more efficient knockdown than the one used here.
Triple knockdown cells were prepared by simultaneous transfection of this PUS10 knockdown strain by siRNAs for TRUB1 and
TRUB2.

Determination of the presence of Ψ at specific
positions in the tRNAs
Total RNA from C57BL/6 mouse livers was prepared using Tri
Reagent (Molecular Research Center) according to the manufacturer’s protocol. To prepare total cellular RNA, a homogenous
suspension of the liver tissue in PBS containing 0.1% NP40 and
protease inhibitor (88665, Pierce Thermo Fisher) was prepared
by a few strokes of Dounce homogenizer. Nuclear and total cytoplasmic extracts were prepared from this suspension as for
HEK293T cells. RNAs were isolated separately from the nuclear
and total cytoplasmic extracts, as well as from the total cellular extracts. tRNAs were separated from other RNAs by PAGE on 6%
denaturing gel and eluted. The presence of Ψ in the tRNA was determined by primer extension following CMCT treatment, as described previously (Deogharia et al. 2019). Briefly, 20 µg tRNAenriched total RNA (6 µg tRNA and 14 µg total RNA) was treated
with CMCT for 20 min at 37°C. Controls were simply untreated
and incubated samples. CMCT-treated RNAs after precipitation
were treated with 50 mM Na2CO3, pH 10.4, for 3 h at 37°C.
The RNAs were precipitated and used for primer extension with
[5′ -32P]-labeled primers using M-MLV reverse transcriptase
(Promega) according to the manufacturer’s instructions.
Reaction products were separated by 12% sequencing gels.
The tRNA-enriched total RNAs from the nuclei and cytoplasm
of mouse liver were used for the CMCT reactions because the
yield of RNAs were higher than those from human cell lines.

Electrophoretic mobility shift assays (EMSA)
Complexes were assembled by incubating ∼1 pmol of 3′ -end-labeled tRNAs with varying concentrations of recombinant proteins
in 20 µL reactions in a buffer (20 mM Tris-Cl, pH 8.0, 150 mM
NaCl, 0.75 mM DTT, 1.5 mM MgCl2, 0.1 mM EDTA, 10% glycerol)
for 15 min at 37°C. Complexes were resolved on native 6% polyacrylamide gel in 0.5× TBE buffer (45 mM Tris-borate, 1 mM
EDTA) run at 4°C. The bands were visualized by using a
phosphorimager.

SUPPLEMENTAL MATERIAL
Supplemental material is available for this article.
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METHODS
PUS1, PUS2 and tRNA Ψ31 synthase activities for use as controls for the tRNA Ψ55
synthase activities in the extracts of TRUB1, TRUB2 and PUS10 knockdown strains
Although TRUB1 and TRUB2 are located in the nucleus and mitochondria, respectively
(Rintala-Dempsey and Kothe 2017), both can produce Ψ27 in tRNAs. To determine this activity,
we treated [α-32P]UTP-labeled tRNAPhe with the extracts and quantitated the amount of labeled
Ψp after RNase T2 digestion of the product, separation by 2D-TLC and phosphorimaging. In
these digests, a labeled modified or unmodified U would be derived from the first of the two
consecutive U's present in the tRNA. Human tRNAPhe contains UU sequences at three positions:
16-17, 27-28 and 54-55 (Supplemental Fig. S1). Dihydrouridine (D), Ψ and T are present at
positions 16, 27 and 54 respectively, in the native human tRNAPhe (Juhling et al. 2009). Dp
sometimes merges with and is indistinguishable from Up in the TLC separations. Generally, Tp
is not produced due to the lack of methyl-donor SAM in the extracts. Previously, by treating the
U27A mutant of tRNAPhe with total cell extracts, we confirmed that the Ψ from [α-32P]UTPlabeled tRNAPhe is derived from U27 (Deogharia et al. 2019). No Ψ was produced in that case. In
the experiments here, we observe labeled Ψp only with the nuclear and mitochondrial extracts,
which would be the products of Ψ27-synthase activities of PUS1 and PUS2, respectively
(Supplemental Fig. S2A). Although, human cytoplasmic PUS10 can convert U54 to a Ψ in
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certain tRNAs, this is not the case here, because it does not produce Ψ54 in tRNAPhe (Deogharia
et al. 2019). This is again confirmed here by the lack of Ψ after treatment with cytoplasmic
extract (Supplemental Fig. S2A, panel at the bottom). The Ψ27 synthase activities of both PUS1
and PUS2 remain nearly the same in the nuclear and mitochondrial extracts of the knockdown
strains when compared with their activities with the extracts of the wild type (Supplemental Fig.
S2A). Therefore, Ψ55 synthase activities in the nuclear and mitochondrial extracts of the
knockdown strains are measured relative to their Ψ27 synthase activities as shown in Fig. 2C.
So far, tRNAMet is the only known cytoplasmic tRNA of eukaryotes that contains Ψ31
(Juhling et al. 2009). Pus6 is reported to produce Ψ31 in the cytoplasmic and mitochondrial
tRNAs of yeast and it is not present in the nucleus (Ansmant et al. 2001). PUSD1 is suggested to
do the same modification in human tRNAs (Spenkuch et al. 2014). Therefore, we used tRNA
Ψ31 synthase activity as a control for cytoplasmic extracts of the knockdown strains. Since U31
of tRNAMet is followed by a C32, we used [α-32P]CTP-labeled tRNAMet to determine the Ψ31
synthase activity of the extracts. However, this tRNA contains UC at four positions: 27-28, 3132, 39-40 and 55-56 (Supplemental Fig. S1). Therefore, we used two mutant versions of this
tRNA. In one case, three U's, i.e., at positions 27, 39 and 55 were changed to C, C and A,
respectively (referred as Mut-tRNAMet in Supplemental Fig. S2B), thus leaving UC only at
position 31-32, and in the other case, U31 was also changed to a C (referred as U31C mut). PCR
products of two oligonucleotides that overlapped at their 3' ends, were used to prepare transcripts
of these two tRNAs. Treatment of the three U's mutant tRNAMet (Mut-tRNAMet) showed labeled
Ψp only with the cytoplasmic extracts, but this was absent when the four U's mutant tRNA was
used (Supplemental Fig. S2B). This suggested that the Ψp observed here is derived from the
position 31. Mitochondrial and nuclear extracts did not show any Ψp (bottom two panels in
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Supplemental Fig. S2B). Apparently our tRNAMet transcript is not a substrate for the human
mitochondrial Ψ31 synthase activity. Sequence of human mitochondrial tRNAMet is very
different from the cytoplasmic tRNAMet and mammalian mitochondrial tRNAMet genes contain G
not T at position 31 (Juhling et al. 2009). Ψ31 synthase activity remains nearly the same in the
cytoplasmic extracts of the knockdown strains when compared with their activities in the wild
type (Supplemental Fig. S2B). Therefore, Ψ55 synthase activities in the cytoplasmic extracts of
the knockdown strains are measured relative to their Ψ31 synthase activity as shown in Fig. 2C.

SUPPLEMENTAL FIGURE LEGENDS
Supplemental Figure S1. Sequences of tRNA transcripts used in this study. The original A-U
pair at position 1-72 of the tRNAiMet was changed to G-C for the ease of transcription. Relevant
Ψ modifications observed in native mammalian tRNAs are shown in parentheses. Mutations of
residues in tRNAAla, tRNAiMet, tRNAAU-Ala and tRNAMet used in this work are indicated.

Supplemental Figure S2. PUS1, PUS2 and tRNA Ψ31 synthase activities of the extracts. (A)
[α-32P]UTP-labeled transcripts of tRNAPhe were incubated with nuclear (NE) and mitochondrial
(ME) extracts of WT and TRUB1, TRUB2, PUS10 knockdown strains of PC3 cells as well as
with extracts where all the three proteins were depleted (All 3-KD). They were analyzed as in
Fig. 1. Ψ in all cases is derived from positions 27 of the tRNAs. Unrelated luciferase knockdown
(siLuc) is a control showing there is no affect in Ψ synthesis due to the transfection itself.
Cytoplasmic extract (CE, bottom panel) showed no Ψ27 synthesis. (B) [α-32P]CTP-labeled
transcripts of Mut-tRNAMet (U27C, U39C and U55A mutations-containing tRNAMet) were
incubated with cytoplasmic (CE) extracts of WT and TRUB1, TRUB2, PUS10 and luciferase
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knockdown strains of PC3 cells as well as with extracts when all the three proteins were depleted
(All 3-KD). They were analyzed as in (A). Absence of Ψ in U31C mutant of this tRNA
(WT+U31C) indicates that Ψ in all cases is derived from positions 31 of these tRNAs. Nuclear
and mitochondrial extracts (bottom two panel) showed no Ψ31 synthesis.

Supplemental Figure S3. Immunoblots of sub-cellular fractions. (A) Purity of nuclear (NE) and
total cytoplasmic (TCE) fractions of HEK293T cells transiently transfected with His-tagged
human PUS10 clone. Blots were probed with antibodies against lamin A (ab26300, Abcam) and
tubulin (ab6046, Abcam), which were used as nuclear and cytoplasmic markers, respectively. (B)
Recombinant proteins isolated from nuclear (nh-PUS10) and total cytoplasmic (ch-PUS10)
fractions shown in (A) are indeed His-tagged PUS10 as determined by anti-PUS10 (HPA049582,
Sigma) and anti-His (2365, Cell Signal Technology) antibodies. (C) Purity of nuclear (NE),
cytoplasmic (CE) and mitochondrial (ME) fractions of PC3 cells were determined by anti-lamin
A, anti-tubulin and anti-porin (ab15895, Abcam) antibodies as nuclear, cytoplasmic and
mitochondrial markers, respectively. (D) Purity of nuclear (NE) and total cytoplasmic (TCE)
fractions of mouse liver cells were determined by using anti-lamin A and anti-tubulin antibodies
as nuclear and cytoplasmic markers, respectively.

Supplemental Figure S4. Determination of protein knock down. (A) Immunoblot analyses of
cell lysates of PC3 cells after performing knockdowns (KD) for TRUB1, PUS10 and TRUB2
showed a decreased amount of these proteins in the cells. Lysates of normal PC3 (WT) and siLuc
transfected PC3 cells were used as controls. Blots were probed with antibodies against TRUB1
(PA5-58163, Invitrogen), PUS10 (HPA049582, Sigma), TRUB2 (sc-514573, Santa Cruz
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Biotechnology) and β-actin (ab8227, Abcam). β-actin was used as the loading control. The blots
were normalized with respect to β-actin and a fold change was calculated with respect to the WT
signal. The fold changes are indicated below each lane in the blot. (B) qPCR was used to
compare the amount of PUS10, TRUB1 and TRUB2 mRNA in PC3 cells after performing
knockdowns (KD) for the proteins. WT and siLuc transfected PC3 cells were again used as a
control. Results are normalized with respect to HPRT mRNA. Values are the mean ± S.E. (n=3).
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Supplemental Table 1: p values
Fig 2C
NE

Trp

WT vs siLuc
WT vs TRUB1 KD
WT vs TRUB2 KD
WT vs PUS10 KD
WT vs
B1+B2+P10

Ala

p value
>0.9999
0.0049
0.4062
0.3853

Summary
ns
**
ns
ns

p value
0.8126
0.0286
0.9999
0.9221

Summary
ns
*
ns
ns

<0.0001

****

0.0022

**

p value
0.7423
0.9898
0.9998
<0.0001

Summary
ns
ns
ns
****

p value
0.9654
0.9996
0.2509
0.0474

Summary
ns
ns
ns
*

<.0001

****

0.0002

***

p value
>0.9999
>0.9999
0.0001
0.984

Summary
ns
ns
***
ns

p value
0.9813
0.9924
0.0002
>0.9999

Summary
ns
ns
***
ns

0.0002

***

0.001

**

Trp

CE
WT vs siLuc
WT vs TRUB1 KD
WT vs TRUB2 KD
WT vs PUS10 KD
WT vs
B1+B2+P10

Ala

Trp

ME
WT vs siLuc
WT vs TRUB1 KD
WT vs TRUB2 KD
WT vs PUS10 KD
WT vs
B1+B2+P10

Ala

Fig 6A

+TRUB1 vs h-PUS10+TRUB1

p value
0.002
0.818
0.02
>0.9999

Trp
Ala
iMet
AU-Ala

Summary
**
ns
*
ns

Fig 6C
Trp
NE vs ch-PUS10+NE
NE vs nh-PUS10+NE
CE vs ch-PUS10+CE
CE vs nh-PUS10+CE

p value
0.009
0.0056
0.1689
0.027

Ala
Summary
**
**
ns
*

*p<0.05,**p<0.01,***p<0.001 and ****p<0.0001, ns = not significant.

p value
0.013
>0.9999
0.0409
0.9999

Summary
*
ns
*
ns

Supplemental Table S2: List of oligonucleotides used in this work and their functions

Oligonucleotide

Sequence

Purpose

Oligonucleotides used for primer extensions

MUTRP3R

TGG TGA CCC CGA CGT

CMCT-primer extension of Trp tRNA

MUGLN3R

TGG AGG TCC CAC CGA

CMCT-primer extension of Gln tRNA

MUALA3R

TGG AGG TGT CGG GGA

CMCT-primer extension of Ala tRNA

MUPHE3R

TGG TGC CGA AAC CCG

CMCT-primer extension of Phe tRNA

MUiMET3R

TGG TAG CAG AGG ATG

CMCT-primer extension of iMet tRNA

MUAU-ALA3R

TGG TGG AGA ATG CGG

CMCT-primer extension of AU-Ala
tRNA

Oligonucleotides used to generate templates for in vitro tRNA transcription

T7HUTRP5F

TAA TAC GAC TCA CTA
TAG GTT CCA TGG TGT
AAT GGT TAG C

HUTRP-3R

TGA CCC CGA CGT GAT
TTG AAC

T7HUALA5F

TAA TAC GAC TCA CTA
TAG GGG GTG TAG CTC
AGT GG

To generate templates to transcribe
Trp tRNA

To generate templates to transcribe
Ala tRNA

HUALA-3R

TGG AGG TGT CGG GGA
TCG AAC CCG AGG

HUALA-3R2

TGG AGG TGT CGG GGA
CCG AAC CCG AGG

To generate A58G mutation in
Ala tRNA

HUALA-3R3

TGG AGG TGT CGG GGA
TCG AGC CCG AGG

To generate U54C mutation in
Ala tRNA

HUALA-3R4

TGG AGG TGT CGG GGA
TCG ACC CCG AGG

To generate U54G mutation in
Ala tRNA

HUALA-3R5

TGG AGG TGT CGG GGA
TCG ATC CCG AGG

To generate U54A mutation in
Ala tRNA

T7HU-iMET5F

HU-iMET-3R

HUiMET-3R2

T7HUAU-ALA5F

HUAU-ALA-3R

HUAU-ALA-3R2

T7HUPHE5F

TAA TAC GAC TCA CTA
TAG GCA GAG TGG CGC
AGC GGA AGC GTG CTG
GGC CC
TGG CAG AGG ATG GTT
TCG ATC CAT CGA CCT
CTG GGT TAT GGG CCC
AGC ACG CTT CC
TGG CAG AGG ATG GCA
TCG ATC CAT CGA CCT
CTG GGT TAT GGG CCC
AGC ACG CTT CC
TAA TAC GAC TCA CTA
TAG GGG AAT TAG CTC
AAA TGG TAG AGC GCT
CGC TTA G
TGG AGA ATG CGG GCA
TCG ATC CCG CTA CCT
CTC GCA TGC TAA GCG
AGC GCT CTA CC
TGG AGA ATG CGG GTT
TCG ATC CCG CTA CCT
CTC GCA TGC TAA GCG
AGC GCT CTA CC
TAA TAC GAC TCA CTA
TAG CCG AAA TAG CTC
AGT TGG G

To generate templates to transcribe
iMet tRNA

To generate AA59-60UG mutation in
iMet tRNA

To generate templates to transcribe
AU-Ala tRNA

To generate UG59-60AA mutation in
AU-Ala tRNA

To generate templates to transcribe
Phe tRNA

TGC CGA AAC CCG GGA
TCG AAC

HUPHE-3R

T7HUMUT-MET5F

HUMUT-MET-3R

HUMUT-MET3R2

T7HUGLN5F

HUGLN-3R

TAA TAC GAC TCA CTA
TAG CCT CGT TAG CGC
AGT AGG TAG CGC GCC
AGT CTC
TGC CCC GTG TGA GGA
TCG TAC TCA CGA CCT
TCA GGT TAT GAG ACT
GGC GCG CTA CC
TGC CCC GTG TGA GGA
TCG TAC TCA CGA CCT
TCA GGT TAT GAG GCT
GGC GCG CTA CC
TAA TAC GAC TCA CTA
TAG GTT CCA TGG TGT
AAT GGT TAG C

To generate templates to transcribe
elongator Met tRNA with U27C,U55A
and U39C change

To generate U27C,U55A, U39C and
U31C mutation in elongator Met tRNA

To generate templates to transcribe
Gln tRNA

AGG TTC CAC CGA GAT
TTG AAC TCG

Oligonucleotides used to generate and check knockdowns

siLuc_ss

GCA CAU AUC GAG GUG
AAC ATT

siLuc_as

UGU UCA CCU CGA UAU
GUG

siTRUB1_ss

GCA GAA GAC AGC UCC
UUU ATT

siTRUB1_as

UAA AGG AGC UGU CUU
CUG CTT

siTRUB2_ss

CCC AGG AGU UUA AGG
UUG UTT

Sense(ss) and Antisense(as) siRNA
sequences used for transient knock-down
of Luciferase gene which was used as a
control

Sense(ss) and Antisense(as) siRNA
sequences used for transient knock-down
of TRUB1 gene

Sense(ss) and Antisense(as) siRNA
sequences used for transient knock-down
of TRUB2 gene

siTRUB2_as

HUPUS10-F

ACA ACC UUA AAC UCC
UGG GTT

CTC ACC AAA GGC TGT
ATG C

HUPUS10-R

CCA AGG AGT TTG TGG
TAG ATT CC

HUTRUB1-F

ACA CAA GAA GAT ATT
GAA GGC A

Primers used to perform qPCR to
estimate the amount of PUS10 mRNA

Primers used to perform qPCR to
estimate the amount of TRUB1 mRNA
HUTRUB1-R

CCT CTC TTC ATC AAA
GTC GAA A

HUTRUB2-F

GCT GAT AAC TGG CAT
CCG ATG C

HUTRUB2-R
HUHPRT-F

GCA GTG GTC TTT AGT
TCC AGG C

Primers used to perform qPCR to
estimate the amount of TRUB2 mRNA

TGACACTGGCAAAACAA
GCA
Primers used to perform qPCR to
estimate the amount of HPRT mRNA

HUHPRT-R

GGTCCTTTTCACCAGCAA
GCT

Oligonucleotides used to clone genes

HUTRUB1-F2

CCT GCC ATG GCC GCT
TCT GAG GCG GCG

Forward primer to clone TruB1 gene
in NcoI (CCATGG) site of pET28a

HUTRUB1-R2

HUTRUB2-F2

HUTRUB2-R2

CTG CTC GAG GCT GCC
GCG CGG CAC CAG ACA
CGT CTT AAT TAC ATC
ATC

Reverse primer to clone TruB1 gene,
has an XhoI (CTCGAG) site and
sequence complementary to codons
of thrombin cut site (GCT GCC GCG
CGG CAC CAG)

CGC TCT AGA AAT TTT
GTT TAA CTT TAA GAA
GGA GAT ATA CCA TGG
GGT CTG CTG GCT TGT

Forward primer to clone TruB2 gene
in XbaI (TCTAGA) site of pET28a

CTG CTC GAG GCT GCC
GCG CGG CAC CAG CTG
CCC CGC ACC CCT C

Reverse primer to clone TruB2 gene,
has an XhoI (CTCGAG) site and
sequence complementary to codons
of thrombin cut site (GCT GCC GCG
CGG CAC CAG).

